Financial releases

Annual 2017 results and business update

Financial calendar 2018

Free allotment of warrants to the shareholders and issue of a convertible bond

FDA grants orphan-drug designation to ZENEO® Midazolam

Business update

Interim 2017 results and business update

Business update Confirmation of the schedule of marketing authorisation filings

CROSSJECT receives €2.9M from Bpifrance as part of the PIAVE financing

CROSSJECT receives authorization to conduct Zeneo® Midazolam bioequivalence study

CROSSJECT boosts its US commercial development efforts